IPInna Prygova

Inna Prygova

*This is an algorithmically generated author record based on publicly available information.

Inna Prygova has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Global Survey of Skin Concerns and Treatment Interests in Perimenopausal and Menopausal Patients

    by Sabrina G. Fabi, Andreas Nikolis, Alessandra Haddad, Luiz Avelar, Katie Beleznay, Doris Day, Steven Dayan, Stephanie Lam, Michael Somenek, Neha Sarcevic, et al.

    OBJECTIVE: To explore factors affecting women undergoing menopause transition, focusing on lifestyle, facial-skin changes, and current aesthetic treatment interests for this. METHODS: Quantitative research (online questionnaire) was undertaken by women aged 45 to 60 years from 9 countries to understand their menopause experiences, determine their level of knowledge and perceptions of menopause, and to gain further insights into their current skin care, as well as understand menopause-related skin changes and skin concerns. RESULTS: Across 4,303 respondents, perimenopause and menopause affected facial wrinkles/fine lines (59%), loss of firmness/elasticity (58%), increased dryness (56%), and duller skin tone (40%), which negatively impacted perceived attractiveness (60% agreed/strongly agreed), creating anxiety or low mood (57% agreed/strongly agreed) and impacting self-confidence (55%). The most common treatments to reduce effects of perimenopause and menopause were food supplements (51%), everyday skincare (47%), and dietary changes (46%). Only 15% of the women used specialist aesthetic treatments for menopause, but 88% of them were satisfied/very satisfied with these treatments reducing the effects of menopause. The main triggers that encouraged the respondents to seek aesthetic treatments were health care professionals’ (HCPs) recommendation (46%), cost-related affordability (40%), and information/education (40%). CONCLUSION: This international survey demonstrated that changes to facial skin during perimenopause and menopause negatively affect perceived facial attractiveness, creating anxiety and reducing self-confidence. Specialist aesthetic treatments might play a key role in reducing the effects of menopause on the skin, with health care professionals aiding understanding.

  • Open Access

    Comment on Honndorf et al. Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA. Toxins 2026, 18, 142

    by Ulf Ståhl, Emil Hamnevik, Åsa Liljegren Sundberg, Cecilia Persson, Inna Prygova

    In their recent paper comparing three complexing protein-free botulinum toxin A products available on the market


  • Open Access

    Midface Projection Using Biostimulatory Poly-l-Lactic Acid Injectable Implant: A Subgroup Analysis of the Cheek Wrinkle Trial

    by Sabrina G. Md Fabi, Jennifer HTD. PharmD Le, Inna Prygova, Daniel Bråsäter

    BACKGROUND: Correction of cheek wrinkles using poly-l-lactic acid (PLLA-SCA) was demonstrated in a 12-month study. OBJECTIVE: This analysis assessed change from baseline in lifting effect of PLLA-SCA using a 3D camera to provide additional quantified data. METHODS: Subjects received PLLA-SCA (reconstituted in 8 mL of sterile water + 1 mL of 2% lidocaine) in both cheeks or no treatment (control). Assessments included the Galderma Cheek Wrinkle Scale (GCWS), aesthetic improvement, and 3D photography. In subjects with severe GCWS at baseline, Canfield software analyzed 3D images for change from baseline in midface volume projection and volume change of both cheeks at Month 9. RESULTS: The primary study showed a statistically significant higher at-rest GCWS responder rate at Month 12 for PLLA-SCA, 71.6%, versus control, 26.1% (p < .0001). In this Month 9 analysis, mean midface volume projection demonstrated a positive volume shift for PLLA-SCA (left: 0.45 mm; right: 0.34 mm; n = 46) versus control (left: 0.25 mm; right: −0.01 mm; n = 21). Midface volume and max projection changes for PLLA-SCA were +4.88 mL/+1.62 mm (left), +2.84 mL/+1.12 mm (right) versus +0.26 mL/+0.34 mm (left), +0.68 mL/+0.37 mm (right) for control. CONCLUSION: Poly-l-lactic acid-treatment of subjects with severe GCWS had a clinically meaningful lifting effect in both cheeks (positive volume shift, positive volume change, and max projection) in the midface. Clinical trial registry number: NCT04124692.


  • Open Access

    Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment

    by Said Hilton, Philippe Kestemont, Gerhard Sattler, Magali Volteau, Catherine Thompson, Bill Andriopoulos, Inna Prygova, Anna-Karin Berg, Benjamin Ascher

    BACKGROUND: AbobotulinumtoxinA (aboBoNT-A) solution is a new ready-to-use formulation developed to reduce preparation time and improve reproducibility of injections. OBJECTIVE: To further evaluate treatment of moderate-to-severe glabellar lines (GLs) using pooled data from 2 Phase III studies. METHODS: Following double-blind treatment with 50 U aboBoNT-A solution (n = 251) or placebo (n = 123), GL severity was assessed by investigators (ILA) and subjects (SSA). Other assessments included subject-reported time to onset, subject satisfaction, FACE-Q, and adverse events. RESULTS: One month after aboBoNT-A solution treatment, 88% had none-or-mild GLs at maximum frown and 93% had ≥1-grade improvement in ILA (similar for SSA), 24% to 27% remaining improved at Month 6. Glabellar lines responder rates remained higher than placebo throughout Month 6 (p < .001). Almost two-thirds of subjects reported onset within 3 days, nearly a quarter reporting effect by Day 1. Subject satisfaction with GL appearance, and FACE-Q satisfaction with facial appearance overall and psychological well-being were also improved over placebo throughout Month 6, p < .05. Treatment-related adverse events were nonserious and mild or moderate. CONCLUSION: Pooled analysis confirmed a duration of effect on GLs of up to 6 months for aboBoNT-A solution, with onset starting within 24 hours, high subject satisfaction, and improved psychological well-being. The treatment was well tolerated.


  • Open Access

    Use of AbobotulinumtoxinA for Cosmetic Treatments in the Neck, and Middle and Lower Areas of the Face: A Systematic Review

    by Hassan Galadari, Ibrahim Galadari, Riekie Smit, Inna Prygova, Alessio Redaelli

    AbobotulinumtoxinA (aboBoNT-A) has been used for various cosmetic purposes, including minimization of moderate to severe lines, or other cosmetic indications, in the face and neck. We carried out a systematic review to identify all relevant evidence on the treatment approaches and outcomes of aboBoNT-A as a cosmetic treatment of the middle and lower areas of the face, and the neck. Embase, MEDLINE, Cochrane Library, congress proceedings and review bibliographies were searched for relevant studies. Identified articles were screened against pre-specified eligibility criteria. Of 560 unique articles identified, 10 were included for data extraction (three observational studies, 1 randomized controlled trial [with two articles] and five non-randomized trials). The articles provided data on gummy/asymmetric smile (2), marionette lines (5), masseter muscle volume (2), nasal wrinkles (2), perioral wrinkles (3) and the platysma muscle (4). All articles reporting on efficacy of aboBoNT-A demonstrated positive results, including reduction of wrinkles (5), reduction of masseter muscle (2) and degree of gummy smile (1) compared with before treatment. No serious adverse events were reported and patient satisfaction was high. In conclusion, positive findings support further research of aboBoNT-A for the middle and lower areas of the face, and in the neck, which are largely unapproved indications.